Australia markets closed

Zelira Therapeutics Limited (ZLD.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.9700-0.0300 (-3.00%)
At close: 03:54PM AEST

Zelira Therapeutics Limited

101 St Georges Terrace
Level 3
Perth, WA 6000
Australia
61 8 6558 0886
https://www.zeliratx.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Osagie O. Imasogie Esq.Founder & Chairman144kN/A1962
Dr. Oludare OdumosuMD, Global CEO & Director371.73kN/AN/A
Mr. Rahul GanesanVP of Fin. & AccountingN/AN/AN/A
Mr. Greg BlakeVP of Global and Head of Commercial & PartneringN/AN/AN/A
Mr. Timothy Ryan SlateNon-Exec. Director & Company Sec.N/AN/AN/A
Dr. Patty WasherClinical Trial ConsultantN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based medicines for the treatment of various medical conditions in Australia. The company is also involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; the Children's Hospital of Philadelphia (CHOP) on opioid reduction study; HAPA Pharm BV; and Ethicann. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was founded in 2003 and is headquartered in Perth, Australia.

Corporate governance

Zelira Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.